

Registered number
03005721

Endocrine Pharmaceuticals Limited

Abbreviated Accounts

30 June 2011

WEDNESDAY



RM99OXQ6
RM 21/09/2011 49
COMPANIES HOUSE

Endocrine Pharmaceuticals Limited**Registered number:** 03005721**Abbreviated Balance Sheet
as at 30 June 2011**

	Notes	2011 £	2010 £
Fixed assets			
Tangible assets	2	158	210
Current assets			
Cash at bank and in hand		5,067	5,940
Creditors: amounts falling due within one year		(42,957)	(36,118)
Net current liabilities		<u>(37,890)</u>	<u>(30,178)</u>
Net liabilities		<u>(37,732)</u>	<u>(29,968)</u>
Capital and reserves			
Called up share capital	3	15,162	14,972
Share premium		2,492,504	2,473,694
Profit and loss account		(2,545,398)	(2,518,634)
Shareholders' funds		<u>(37,732)</u>	<u>(29,968)</u>

The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006

Members have not required the company to obtain an audit in accordance with section 476 of the Act

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts

The accounts have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006 applicable to companies subject to the small companies regime



Dr J E Hart
Director

Approved by the board on 9 September 2011

Endocrine Pharmaceuticals Limited
Notes to the Abbreviated Accounts
for the year ended 30 June 2011

1 Accounting policies

Basis of preparation

The accounts have been prepared under the historical cost convention and in accordance with the Financial Reporting Standard for Smaller Entities (effective April 2008)

Depreciation

Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives

Plant and machinery 25% on written down value

Fundamental accounting concept

The accounts have been prepared on the going concern basis which assumes that the company will continue in operational existence for the foreseeable future. During the year the company incurred a loss of £26,764. The company is involved in research and Development activities and while the company may require financial support from additional investments it is endeavouring to become cash positive via deals with industrial partners, and most recently, by taking steps to market products direct to potential users.

The directors are thus actively seeking further finance. Whilst the directors cannot be certain of future funding, based on the progress to date, they believe that it is appropriate for these statutory accounts to be prepared on a going concern basis.

2 Tangible fixed assets	£
Cost	
At 1 July 2010	886
At 30 June 2011	<u>886</u>
Depreciation	
At 1 July 2010	676
Charge for the year	<u>52</u>
At 30 June 2011	<u>728</u>
Net book value	
At 30 June 2011	<u>158</u>
At 30 June 2010	<u>210</u>

3 Share capital	Nominal value	2011 Number	2011 £	2010 £
Allotted, called up and fully paid				
Ordinary shares	10p each	5,831,647	5,832	5,704
A Ordinary shares	10p each	9,331,474	<u>9,330</u>	<u>9,268</u>
			<u>15,162</u>	<u>14,972</u>
	Nominal value	Number	Amount £	
Shares issued during the period				
Ordinary shares	10p each	127,500	128	
A Ordinary shares	10p each	62,500	<u>62</u>	
			<u>190</u>	